Alembic Pharma Wins USFDA Approval for Dapagliflozin Tablets Kumar Jeetendra | April 7, 2026 Alembic Pharmaceuticals Limited (Alembic) today announced that it has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Dapagliflozin Tablets, 5 mg and 10 mg. Alembic Pharmaceuticals Limited Gets USFDA Approval for Dapagliflozin Tablets The approved ANDA is therapeutically equivalent to the reference listed drug product …
